Compare F5 Inc (FFIV) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Incyte Corporation — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: F5 Inc and Incyte Corporation are close in size by market cap, and F5 Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Incyte Corporation for 33 Days on average.
| FFIV | INCY | |
|---|---|---|
Market Cap | $26.14B | $22.85B |
Volume | 503,146 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $479.83 | $129.93 |
52-Week Low | $223.99 | $83.80 |
Typical Hold Time | 38 Days | 33 Days |
Enterprise Value | $24.78B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $4.73 surpassing the $4.00 consensus, and maintains robust profitability with a net income margin of 21.95%. Recent news highlights leadership in WAAP platforms and AI security partnerships, reinforcing growth prospects.
The stock offers upside potential driven by earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 36.78 suggest premium pricing. Key risks include competitive pressures and market volatility, while analyst consensus leans neutral with a $416.60 price target below the current price, indicating cautious optimism tempered by valuation concerns.
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
